We are presenting at the 27th Annual @American Society of Gene & Cell Therapy (#ASGCT)
Save the date! We are presenting at the 27th Annual @American Society of Gene & Cell Therapy (#ASGCT) Meeting next week in Baltimore, MD! 📌 Abstract Title: S/MAR-Containing AAV Vectors Result in an Increase in AVV Episomes & a Reduction in AAV Integration Sites in a Mouse Model with a High Rate of Hepatocyte Proliferation
Our CEO Jean-Philippe Combal will join a panel of key industry leaders at the 10th Annual LSX World Congress
We’re thrilled to share that our CEO Jean-Philippe Combal will join a panel of key industry leaders at the 10th Annual LSX World Congress to provide insight on best practices, strategies and real-life experiences that drive innovation in cell and gene therapy (#CGT).
Vivet Therapeutics to Participate and Present at Upcoming Scientific and Investor Conferences in April through to June 2024
Paris, France, April 23, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, is pleased to announce that its management team will be participating and presenting at the following scientific and business conferences in April, May and June in 2024.
Round table discussion on ‘Therapeutic Advances’ on the ‘Current Situation of Rare Diseases in Spain’.
Vivet Therapeutics Co-founder and Chief Scientific Officer, Gloria Gonzalez-Aseguinolaza will be participating in a round table discussion on ‘Therapeutic Advances’ on the ‘Current Situation of Rare Diseases in Spain’.
Cell & Gene Meeting on the Med
Vivet Therapeutics is heading to Rome for the 2024 Cell & Gene Meeting on the Med from 9 – 11 April. Come and listen to our CEO, @Jean-Philippe Combal on 9 April at 10am CEST, where he will deliver a presentation on hashtag#Vivet‘s diversified pipeline of hashtag#rAAV based hashtag#genetherapies for rare inherited liver metabolic disorders […]
7th Annual Gene Therapy for Rare Disorders Summit
Vivet Therapeutics Chief Executive Officer, Jean-Philippe Combal will be attending the 7th Annual Gene Therapy for Rare Disorders Summit, taking place from 26-29 March in Boston, MA!
J.P.Morgan 2024 – Annual Healthcare Conference in San Francisco
Jean-Philippe Combal – CEO and Gloria Gonzalez – CSO, are going to San Francisco for #JPM24! Let’s make the most of this opportunity. Please send a message if you would like to schedule a meetup: info@vivet-therapeutics.com. #Wilsonsdisease #genetherapy #innovation #letsconnect
Vivet spronsoring and attending the Spanish Wilson disease patients association annual conference in Valencia, Spain
The Vivet Therapeutics team had the honor of sponsoring and attending the Spanish Wilson’s Disease Association meeting in Valencia, Spain (learn more: https://lnkd.in/eUMB-AUw ) over the last weekend.
AASLD – The Liver Meeting in Boston
Vivet Therapeutics is pleased to join AASLD – The Liver Meeting in Boston, MA this year. Meet with Vivet Therapeutics for an update on the GATEWAY gene therapy clinical trial for Wilson disease – booth B908
ESGCT’s 30th Annual Congress in Brussels
Excited to kick off ESGCT’s 30th Annual Congress in Brussels today! Join Vivet’s New Programs and Innovation Lead @Nicholas Weber, Ph.D. as he presents on the topic “Gene Therapy for Metabolic Diseases” on 25 October at 2:30 pm.